Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer

Pharmacogenetics and Genomics

Volumn 19, Issue 11, 2009, Pages 833-842

  Lee, Soo Chin ^a   Xu, Xin ^a   Chng, Wee Joo ^a   Watson, Mark ^b   Lim, Yi Wan ^a   Wong, Chiung Ing ^a   Iau, Philip ^b   Sukri, Norita ^a   Lim, Siew Eng ^a   Yap, Hui Ling ^a   Buhari, Shaik Ahmad ^b   Tan, Patrick ^b   Guo, Jiayi ^a   Chuah, Benjamin ^a   McLeod, Howard L ^c   Goh, Boon Cher ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer; Chemotherapy response; Gene expression

Indexed keywords

DOCETAXEL; DOXORUBICIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MULTIVARIATE ANALYSIS; REPRODUCIBILITY OF RESULTS; TAXOIDS; TREATMENT OUTCOME;

EID: 74049096702     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328330a39f     Document Type: Article

References (24)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
3. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569. (Pubitemid 44200649)
4. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005; 102: 3738-3743. (Pubitemid 40354681)
5. Paik S, Shak S, Tang G, Kim C, Baker J, Cronln M, et al. A multigene assay to predict recurrence of tamoxlfen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
6. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369. (Pubitemid 36957839)
7. Ayers M, Symmans WF, Stec J, Damokosh Al, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy In breast cancer. J Clin Oncol 2004; 22: 2284-2293. (Pubitemid 41115384)
8. Thuerlgen O, Schneewelss A, Toedt G, Warnat P, Hahn M, Kramer H, et al. Gene expression signature predicting pathologic complete response with gemcltabine, eplrubicin and docetaxel in primary breast cancer. J Clin Oncol 2006; 24: 1839-1845. (Pubitemid 46638981)
9. Iwao-Kolzuml K, Matoba R, Ueno N, Kim SJ, Ando A, Mlyoshl Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422-431. (Pubitemid 46224217)
10. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/ BIG 00-01 clinical trial. Lancet Oncol 2007; 8: 1071-1078. (Pubitemid 350182953)
11. Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003; 34: 85-90. (Pubitemid 36548796)
12. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 2006; 5: 2914-2918. (Pubitemid 44849019)
13. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005; 11: 951s-958s. (Pubitemid 40111111)
14. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. Prognostic value of Ki67 expression after short-term presurgloal endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-170.
15. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116: 53-68.
16. Van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
17. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature 2006; 439: 353-357.
18. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast oancer-a study from the IMPACT trialists. J Clin Oncol 2005; 23: 2477-2492. (Pubitemid 47050838)
19. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23: 1169-1177. (Pubitemid 46202273)
20. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002; 8: 461-468.
21. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004; 10: 6418-6431. (Pubitemid 39346536)
22. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785. (Pubitemid 351264391)
23. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027. (Pubitemid 46622110)
24. Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE, et al. Chemotherapy-induced tumor gene expression changes in human breast cancers. Pharmacogenet Genomics 2009; 19: 181-192.